AU2005245572B9 - Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib - Google Patents

Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib Download PDF

Info

Publication number
AU2005245572B9
AU2005245572B9 AU2005245572A AU2005245572A AU2005245572B9 AU 2005245572 B9 AU2005245572 B9 AU 2005245572B9 AU 2005245572 A AU2005245572 A AU 2005245572A AU 2005245572 A AU2005245572 A AU 2005245572A AU 2005245572 B9 AU2005245572 B9 AU 2005245572B9
Authority
AU
Australia
Prior art keywords
mammal
compound
proliferative disease
responsive
cell proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2005245572A
Other languages
English (en)
Other versions
AU2005245572B2 (en
AU2005245572A1 (en
Inventor
Daniel Hagerstrand
Goran Hesselager
Monica Nister
Arne Ostman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
UPPSALA UNIVERSITY HOSPITAL
Original Assignee
Ludwig Institute for Cancer Research Ltd
Uppsala Univ Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0410883A external-priority patent/GB0410883D0/en
Priority claimed from GB0425257A external-priority patent/GB0425257D0/en
Application filed by Ludwig Institute for Cancer Research Ltd, Uppsala Univ Hospital filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2005245572A1 publication Critical patent/AU2005245572A1/en
Application granted granted Critical
Publication of AU2005245572B2 publication Critical patent/AU2005245572B2/en
Publication of AU2005245572B9 publication Critical patent/AU2005245572B9/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2005245572A 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib Expired - Fee Related AU2005245572B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0410883.3 2004-05-14
GB0410883A GB0410883D0 (en) 2004-05-14 2004-05-14 Organic compounds
GB0425257.3 2004-11-16
GB0425257A GB0425257D0 (en) 2004-11-16 2004-11-16 Organic compounds
PCT/EP2005/005269 WO2005113801A2 (en) 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib

Publications (3)

Publication Number Publication Date
AU2005245572A1 AU2005245572A1 (en) 2005-12-01
AU2005245572B2 AU2005245572B2 (en) 2008-12-04
AU2005245572B9 true AU2005245572B9 (en) 2009-01-29

Family

ID=35295424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005245572A Expired - Fee Related AU2005245572B9 (en) 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib

Country Status (9)

Country Link
US (1) US20080199855A1 (enExample)
EP (1) EP1756306A2 (enExample)
JP (1) JP2007536920A (enExample)
AU (1) AU2005245572B9 (enExample)
BR (1) BRPI0511088A (enExample)
CA (1) CA2564654A1 (enExample)
MX (1) MXPA06013079A (enExample)
RU (1) RU2006144122A (enExample)
WO (1) WO2005113801A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132336A1 (en) * 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
BR112012004237A8 (pt) * 2009-08-25 2016-10-04 Berg Pharma Llc métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)
EA201691257A1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
WO2003097830A1 (fr) * 2002-05-22 2003-11-27 Japan Represented By President Of The University Of Tokyo Procede pour evaluer la sensibilite a l'imatinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829154B1 (fr) * 2001-09-05 2003-10-17 Assist Publ Hopitaux De Paris Nouveau procede de detection d'une mutation en phase de lecture dans une sequence codante et appareil pour sa mise en oeuvre

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
WO2003097830A1 (fr) * 2002-05-22 2003-11-27 Japan Represented By President Of The University Of Tokyo Procede pour evaluer la sensibilite a l'imatinib

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Affimetrix GeneChip Human Genome U133 Array se HG-U133A" (2002) *
Database Sanger [Online] Sanger Lab: "human cDNA arrays" XP002355610 *
Jendrossek, V., et al; Expert Opinion on Investigational Drugs 2003 United Kingdom; Vol 12 (12): 1899-1924 *
Newton, H. B., Expert Review of Anticancer Therapy (2003); Vol 3 (5): 595-614 *

Also Published As

Publication number Publication date
RU2006144122A (ru) 2008-06-20
CA2564654A1 (en) 2005-12-01
MXPA06013079A (es) 2007-10-08
US20080199855A1 (en) 2008-08-21
AU2005245572B2 (en) 2008-12-04
AU2005245572A1 (en) 2005-12-01
JP2007536920A (ja) 2007-12-20
EP1756306A2 (en) 2007-02-28
BRPI0511088A (pt) 2007-12-26
WO2005113801A2 (en) 2005-12-01
WO2005113801A3 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
US20240124937A1 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
EP1751309B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
Hägerstrand et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
ES2375865T3 (es) Método para predecir la respuesta a agentes bloqueadores del tnf.
CA2850175C (en) Biomarkers for predicting sensitivity to cancer treatments
EP1960547A2 (en) Effects of inhibitors of fgfr3 on gene transcription
KR20060002012A (ko) 방법
US20110020365A1 (en) Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma
JP6549147B2 (ja) Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ
EP1611890B1 (en) Methods for assessing and treating cancer
AU2005245572B9 (en) Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
WO2009023172A2 (en) Predictions of responsiveness to egfr inhibitors
AU2004202980B2 (en) Methods for assessing and treating leukemia
WO2012052758A1 (en) Response biomarkers for iap antagonists in human cancers
MXPA06003826A (es) Biomarcadores para la prediccion de diarrea inducida por farmaco.
JP2022517563A (ja) タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置
CN1997755A (zh) 对伊马替尼治疗敏感的胶质母细胞瘤亚群的鉴定和表征
CN101586152A (zh) 预测表皮生长因子受体抑制剂疗效的试剂盒
EP2508619A1 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-EGFR antibody in patients with colorectal cancer of all UICC stages
KR20070031902A (ko) 이매티닙을 사용하는 치료에 대하여 감수성인아교모세포종의 서브세트의 확인 및 특성화
Kouwenhoven et al. Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
AU2017201083A1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients

Legal Events

Date Code Title Description
SREP Specification republished
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee